- By Amanda Jacquart, MS, LCGC
- Posted June 2, 2026
The Gene Team: MLH3
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Frankie Fann, MS, CGC
- Posted March 25, 2026
The CARE Difference: A Smarter Workflow for High‑Risk Screening
Patients with elevated cancer risks are often unidentified within healthcare systems for a variety of reasons, including fragmented workflows and limited access to cancer risk assessment tools. Danielle Rogers recently shared her experience with providing personalized assessments of cancer risks before and after implementation of the Ambry CARE…
- By Haaniya Mallick, MS, CGC
- Posted March 17, 2026
The Gene Scene: CASQ2
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Katherine Crawford, MS, CGC
- Posted December 30, 2025
The Gene Scene: RET
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Kristina Garcia, MGCS, CGC
- Posted December 9, 2025
The Gene Scene: MEN1
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified early.…
- By Sarah Campian, MS, CGC
- Posted October 21, 2025
The Gene Scene: MSH2
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified…
- By Kimia Sanati, MS, CGC
- Posted October 14, 2025
The Gene Scene: CDKN2A
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications.* These genes are included because they’re linked to serious but preventable or manageable conditions when identified…
- By Candela Delucchi
- Posted August 26, 2025
Making Waves: Honoring a Mother’s Final Wish Through Creative Care
Meet Arravinth (Avi) Anantharajah, MS, LCGC, a genetic counselor with the Cancer Risk Evaluation Program at the University of Pennsylvania’s Basser Center for BRCA. In our Making Waves series, we’ve spotlighted the inspiring work of healthcare providers across our industry. Learn the remarkable story of one family’s determination to complete…
- By Bradley Power, MS, CGC
- Posted August 5, 2025
The Gene Scene: TGFBR1
Welcome to the Gene Scene! Each week, we will explore a gene from the ACMG Secondary Findings list—genes identified by the American College of Medical Genetics and Genomics as having clear, actionable health implications. These genes are included because they’re linked to serious but preventable or manageable conditions when identified…
- By Carrie Horton, MS, CGC
- Posted May 30, 2024
Research Recap: Determining Gene-Disease Validity in POT1 Tumor Predisposition
Germline variants in POT1 have been implicated in predisposition to melanoma, sarcoma and glioma. However, these tumor associations have been derived from very small studies, or those with cohorts highly ascertained for specific cancers. In our recent study in Genetics and Medicine regarding POT1 tumor predisposition syndrome, Ambry set out to…